Evolus, Inc. (0K16.L)
USD 11.39
(0.03%)
USD 11.39
(0.03%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 189.75 Million USD | 14.1% |
| 2022 | 150.3 Million USD | 25.51% |
| 2021 | 119.75 Million USD | 11.98% |
| 2020 | 106.93 Million USD | -12.13% |
| 2019 | 121.69 Million USD | 241.45% |
| 2018 | 35.64 Million USD | 203.96% |
| 2017 | 11.72 Million USD | -41.27% |
| 2016 | 19.96 Million USD | -35.55% |
| 2015 | 30.98 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 47.2 Million USD | 3.88% |
| 2024 Q2 | 52.5 Million USD | 11.23% |
| 2023 FY | 171.5 Million USD | 14.1% |
| 2023 Q2 | 43.62 Million USD | 9.16% |
| 2023 Q1 | 39.96 Million USD | 2.21% |
| 2023 Q3 | 48.02 Million USD | 10.08% |
| 2023 Q4 | 45.43 Million USD | -5.39% |
| 2022 Q2 | 41.27 Million USD | 18.51% |
| 2022 Q4 | 39.1 Million USD | 5.43% |
| 2022 Q3 | 37.09 Million USD | -10.15% |
| 2022 FY | 150.3 Million USD | 25.51% |
| 2022 Q1 | 34.83 Million USD | 0.61% |
| 2021 Q1 | 23.55 Million USD | -21.47% |
| 2021 Q2 | 28.71 Million USD | 21.94% |
| 2021 Q3 | 32.9 Million USD | 14.6% |
| 2021 Q4 | 34.62 Million USD | 5.21% |
| 2021 FY | 119.75 Million USD | 11.98% |
| 2020 Q2 | 19.35 Million USD | -42.32% |
| 2020 FY | 106.93 Million USD | -12.13% |
| 2020 Q3 | 24.03 Million USD | 24.19% |
| 2020 Q4 | 29.98 Million USD | 24.76% |
| 2020 Q1 | 33.55 Million USD | 4.31% |
| 2019 Q3 | 32.79 Million USD | -9.86% |
| 2019 FY | 121.69 Million USD | 241.45% |
| 2019 Q4 | 32.17 Million USD | -1.89% |
| 2019 Q2 | 36.37 Million USD | 78.71% |
| 2019 Q1 | 20.35 Million USD | 51.82% |
| 2018 Q2 | 7.9 Million USD | 53.55% |
| 2018 FY | 35.64 Million USD | 203.96% |
| 2018 Q4 | 13.4 Million USD | 45.91% |
| 2018 Q3 | 9.18 Million USD | 16.32% |
| 2018 Q1 | 5.14 Million USD | 80.02% |
| 2017 Q2 | 2.27 Million USD | -42.8% |
| 2017 Q3 | 2.61 Million USD | 14.99% |
| 2017 Q1 | 3.97 Million USD | 7.34% |
| 2017 FY | 11.72 Million USD | -41.27% |
| 2017 Q4 | 2.85 Million USD | 9.25% |
| 2016 Q4 | 3.7 Million USD | -10.94% |
| 2016 Q2 | 6.05 Million USD | 0.0% |
| 2016 Q3 | 4.16 Million USD | -31.27% |
| 2016 Q1 | 6.05 Million USD | 0.0% |
| 2016 FY | 19.96 Million USD | -35.55% |
| 2015 FY | 30.98 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | 23.269% |
| Dynavax Technologies Corporation | 219.14 Million USD | 13.409% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 64.129% |
| Perrigo Company plc | 1.52 Billion USD | 87.585% |
| Illumina, Inc. | 3.81 Billion USD | 95.023% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 98.149% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 57.924% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 99.533% |
| IQVIA Holdings Inc. | 2.05 Billion USD | 90.757% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -57.271% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 93.26% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -324.83% |
| Waters Corporation | 943.51 Million USD | 79.888% |
| Biogen Inc. | 5.2 Billion USD | 96.354% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 17.02% |
| Adicet Bio, Inc. | 152.03 Million USD | -24.81% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -33.199% |
| bluebird bio, Inc. | 240.23 Million USD | 21.01% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 30.209% |
| FibroGen, Inc. | 398.11 Million USD | 52.335% |
| Agilent Technologies, Inc. | 2.11 Billion USD | 91.028% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1264.226% |
| Homology Medicines, Inc. | 9.87 Million USD | -1821.61% |
| Geron Corporation | 70.44 Million USD | -169.387% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 89.458% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 55.628% |
| Myriad Genetics, Inc. | 600.1 Million USD | 68.379% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -88.203% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 65.596% |
| Zoetis Inc. | 2.76 Billion USD | 93.137% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -291.24% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 82.581% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 89.133% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 96.026% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -384.66% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 75.659% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 31.17% |
| Verastem, Inc. | 92.08 Million USD | -106.072% |
| Nektar Therapeutics | 190.9 Million USD | 0.599% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 60.165% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -1462.96% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 86.056% |
| OPKO Health, Inc. | 574.68 Million USD | 66.98% |
| Exelixis, Inc. | 1.58 Billion USD | 88.041% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 88.114% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 48.521% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -240.338% |
| uniQure N.V. | 285.08 Million USD | 33.438% |
| Imunon, Inc. | 21.03 Million USD | -802.307% |
| Blueprint Medicines Corporation | 722.86 Million USD | 73.749% |
| Insmed Incorporated | 949.26 Million USD | 80.01% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 36.603% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 53.582% |
| TG Therapeutics, Inc. | 198.47 Million USD | 4.391% |
| Incyte Corporation | 1.19 Billion USD | 84.06% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 81.824% |